|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glial cell line-derived neurotrophic factor (GDNF) is able to protect and repair dopamine neurons in vitro and in animal models of PD, but the clinical use of GDNF is complicated by its pharmacokinetic properties.
|
31840869 |
2020 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of glial cell line-derived neurotrophic factor and multiple neurotransmitters: In relation to cognitive performance in Parkinson's disease with mild cognitive impairment.
|
31650626 |
2020 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glial cell line-derived neurotrophic factor (GDNF) has neurotrophic activity for the survival of dopaminergic neurons, which is under active investigation for Parkinson's disease (PD) therapy.
|
31669104 |
2020 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings highlight the importance of Pitx3-GDNF interplay in dopamine signaling and indicate that our strategy might be useful for the restoration of DAergic fate of NT2 cells to make them clinically applicable toward cell replacement therapy of PD.
|
31310388 |
2020 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the potential protective effects of EA on dopaminergic neurons in a mouse model of PD and whether these effects are associated with the promotion of endogenous brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF).
|
31644786 |
2020 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data indicate that SINEUP-GDNF could represent a new strategy to increase endogenous GDNF protein levels in a more physiological manner for therapeutic treatments of PD.
|
31495777 |
2020 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, in contrast to BDNF and GDNF mRNA levels, BDNF and GDNF protein levels were lower in almost all PD-derived TDNs than in HD-derived cells, thus indicating the dysregulation of NTF expression at the post-transcriptional level.
|
31820346 |
2020 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results provide proof-of-principle that intranasal administration of pGDNF DNA NPs can offer a non-invasive, non-viral gene therapy approach for early-stage PD.
|
29779176 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
|
30808022 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson's disease models.
|
31004735 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the PD hippocampus, protein levels of glial cell line-derived neurotrophic factor were significantly decreased, despite no evidence of neuronal loss.
|
31033033 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that GDNFv may be a promising drug candidate for the treatment of PD.
|
29857941 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, GDNF-transfected macrophages represent a promising therapeutic strategy for PD at both late- and early-stages of the disease.
|
31678095 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glial cell-line derived neurotrophic factor (GDNF) is a promising therapeutic molecule to treat Parkinson's disease.
|
30531868 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Three growth factors, glial cell-line derived neurotrophic factor (GDNF), neurturin (NRTN) and platelet-derived growth factor (PDGF-BB) have been tested in clinical trials in Parkinson's disease (PD) during the past 20 years.
|
30947516 |
2019 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While among these iridoids, catalpol, 10-O-trans-p-coumaroylcatalpol, geniposide and harpagoside, in PD improved the expressions of GDNF and Bcl-2 proteins and TH-positive neurons by increasing the levels of antioxidant enzymes, SOD and GSH-P<sub>X</sub> and down-regulating insulin/IGF signalling via activation of MEK protein.
|
30877973 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings highlight the importance of astroglial GDNF in cinnamon- and NaB-mediated protection of the nigrostriatum in MPTP mouse model of PD and suggest possible therapeutic potential of cinnamon and NaB in PD patients.
|
31119595 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glial cell line-derived neurotrophic factor (GDNF) improved motor function in Parkinson's disease (PD) patients in Phase I clinical trials, and these effects persisted months after GDNF discontinuation.
|
31538765 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
|
30829619 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because GDNF has been effective in animal models of Parkinson's disease, stroke, epilepsy, and Huntington's disease, among other debilitating neurodegenerative diseases, encapsulated cell-based delivery of GDNF might represent one innovative means of slowing the neural degeneration seen in a myriad of currently untreatable neurological diseases.
|
30984255 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data support further development of this HSCT-based macrophage-mediated GDNF delivery approach in order to address the unmet need for a disease-modifying therapy for PD.
|
29615705 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, significant reduction of MDA levels and improvement of activities of CAT, SOD, and GSH-px were observed after GDNF and GGA treatment in the PD model and H<sub>2</sub> O<sub>2</sub> or MPP<sup>+</sup> -induced PC12 cells.
|
29377238 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glial cell line-derived neurotrophic factor (GDNF) and its related neurturin (NRTN) can protect DA neurons in the neurotoxin but not α-synuclein animal models of PD, it failed in the clinical trials.
|
29959908 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDNF was originally identified as a neurotrophic factor crucially involved in the survival of dopaminergic neurons of the nigrostriatal pathway and is currently an established therapeutic target in Parkinson's disease.
|
30059726 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ultrasound-Triggered Effects of the Microbubbles Coupled to GDNF Plasmid-Loaded PEGylated Liposomes in a Rat Model of Parkinson's Disease.
|
29686604 |
2018 |